Login to Your Account

Circassia coughs up a phase III hairball in cat allergy study

By Nuala Moran
Staff Writer

Monday, June 20, 2016

LONDON – Circassia Pharmaceutical plc's lead immunotherapy program has flopped in a phase III 1,200 -subject trial in cat allergy, sending the shares of the UK's most valuable biotech crashing down by 66 percent.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription